• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Capital Rx Launches Clearinghouse Model to Bring Price Visibility to Prescription Drug Costs

by Fred Pennic 09/04/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Capital Rx Brings Price Visibility to Prescription Drug Costs With The Launch of Industry First Clearinghouse Model

Quick Glance

– Capital Rx launches new innovative Clearinghouse Model, a new pricing framework that will itemize the actual unit cost for all drugs for the first time

– The Clearinghouse Model will eliminate price variability for customers, ensuring that drug costs are the same for all customers.

– Pharmacies in its retail network, which includes chains, like Walmart, Walgreens, to grocers and independent pharmacies, will be able to deliver the lowest prescription prices to customers.

– While rising drug prices have made headlines, the price variability and PBM profit margins contributing to this have remained overlooked and unaddressed. 

Capital Rx, an NYC-based next-generation pharmacy benefits manager (PBM), today announced the launch of its Clearinghouse Model, the first major innovation in the way prescriptions are priced for over three decades. Through this new pricing framework, Capital Rx brings full visibility to drug unit prices and eliminates arbitrary price variability for patients and employers.

National Average Drug Acquisition Cost

Capital Rx’s Clearinghouse Model deploys the National Average Drug Acquisition Cost (NADAC), which is maintained by the Centers for Medicare and Medicaid (CMS) based on surveys of actual acquisition costs among retail pharmacies.  With a NADAC benchmark, Capital Rx utilizes on an unbiased source that also ensures price consistency because NADAC prices only update when changes of +/-2% occur. In addition, Capital Rx ‘s contracts with employers offer an industry-first- actual unit costs for all drugs, that is the same for all customers. In comparison, typical PBM agreements are over 50 pages but do not include a single prescription price.

The Bigger Picture

Currently, different employer groups are paying wildly different drug prices because of existing “spread” opportunities for traditional PBMs. While rising drug prices have made headlines, the price variability and PBM profit margins contributing to this have remained overlooked and unaddressed.

“Everyone knows drug prices are rising at alarming rates, but the most interesting metrics we’ve been following over the years are price variability and PBM profit margins,” said AJ Loiacono, CEO of Capital Rx. “Gaps between AWP and acquisition cost create large “spread” opportunities for traditional PBMs. In this model, different employer groups pay wildly different drug prices, and two patients in the same plan can be charged different prices, even when standing in the same pharmacy. This absurd process ends with the introduction of the Clearinghouse Model.”

 The Clearinghouse Model will eliminate price variability for customers, ensuring that drug costs are the same for all customers. Pharmacies in its retail network, which includes chains, like Walmart, Walgreens, to grocers and independent pharmacies, will be able to deliver the lowest prescription prices to customers.

“When Capital Rx approached us with the Clearinghouse Model, we immediately recognized a common goal and shared vision,” said Luke Kleyn, Vice President, Walmart Health and Wellness. “Walmart is working with Capital Rx to deliver the lowest prescription prices and enable our customers to live better.  “Under the Clearinghouse Model, employers and plan sponsors will have direct visibility to the value provided by Walmart.”

Why It Matters

“Capital Rx was founded with the mission to fix the issues plaguing the existing pharmacy benefits model and to address shortcomings in the prescription supply chain.” Loiacono concluded, “Rather than expend resources supporting a system that conflates opacity with earnings, we focus our efforts on improving service and patient outcomes through data-driven programs. The Clearinghouse Model we’re launching is a key first step, establishing a simple framework that allows us to move the conversation past validating artificial pricing guarantees.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Capital Rx, CMS, Drug-Pricing Transparency, medicaid, medicare, Pharmacy, pharmacy benefit manager (PBM), Walgreens, Walmart

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |